新天药业: 第八届董事会第二次会议决议公告

Group 1 - The company held its eighth board meeting on August 21, 2025, with all nine directors present, and the meeting complied with relevant laws and regulations [1] - The board approved a proposal to increase investment in the associated company Shanghai Huilun Pharmaceutical Co., Ltd. by using self-owned funds of 40 million yuan, which includes 20 million yuan for capital increase and 20 million yuan for equity transfer [1][2] - The capital increase and equity transfer will result in the company acquiring 235,294.1 shares of Huilun Pharmaceutical, with a total investment of 360 million yuan after the transaction [2] Group 2 - The agreed capital increase and share transfer price is 8.5 yuan per share, valuing Huilun Pharmaceutical at 3.36 billion yuan prior to the capital increase [2] - Following the transaction, the company's ownership in Huilun Pharmaceutical will increase from 14.5971% to 15.4567% [2] - The voting results for the proposal were 4 votes in favor, 0 against, and 0 abstentions, with 5 directors abstaining due to conflicts of interest [2]